Latest Headlines

Latest Headlines

Bayer hits the gas on its top cancer prospect with Phase III in sight

Bayer is plotting a pair of Phase III trials for its lead oncology treatment, hoping to crack the crowded field of new blood cancer drugs with a targeted therapy of its own.

CEO Dekkers' legacy at Bayer? Embracing risk, à la its American rivals

Marijn Dekker's time in the Bayer CEO chair is winding down, and the Dutchman has a couple of big items left on his to-do list before he turns over the reins. But thanks to his penchant for risk-taking, in the 5-plus years he's been with the German pharma, he's gotten plenty done already.

FDA to investigate Bayer's birth control device after allegations of fraud during clinical trial

The FDA has agreed to investigate Bayer's Essure birth control device, following complaints of fraud during the clinical trial and dangerous side effects.

Bayer signs cardiovascular genomics alliance with Harvard, MIT

Germany's Bayer already partners with MIT and Harvard on oncology research, and now the partnership is being upgraded to include cardiovascular genomics and drug discovery. The expansion of the alliance into cardiovascular genomics will be about the search for genetic biomarkers of patient risk or suitability to particular drugs that treat cardiovascular conditions like heart disease.

Bayer taps the Broad Institute for cardio R&D

Bayer is deepening its ties with Harvard and MIT's Broad Institute, delving into cardiovascular genomics in hopes of spotlighting new therapeutic approaches to deadly diseases.

Panasonic Healthcare offer for Bayer diabetes device biz drops to $830M from $2.3B

The latest of nearly 5 months of speculation has Panasonic Healthcare counting on paying only $830 million for Bayer's diabetes device business it has been trying to sell off. Previous estimates had guessed a sale of up to $2.3 billion.

South Korea tells Bayer to divest oral contraceptives business

Bayer Korea has been ordered to divest its oral contraceptives business, chiefly its Mercilon (ethinylestradiol) drug, which it acquired when its Germany parent Bayer bought Merck's consumer-care business recently.

Ambitious Bayer puts up $27B sales goal for 2017, with OTC carrying a big load

Bayer has already said it plans to home in on life sciences after it carves out its plastics unit later this year for an IPO or spinoff. So what, exactly, does that mean for its HealthCare division, numbers-wise?

Bayer puts cancer-fighting country crooner onstage to promote colonoscopies

As it prepares to streamline itself and rebrand as a life-sciences-focused company, Bayer is counting on colorectal cancer drug Stivarga to chip in to its sales haul--big time. But the drug can only go so far if people don't get checked for the lethal cancer.

Whack-a-mole begins as Natco Sovaldi copies sprout in Nepal, Bangladesh

Want Sovaldi (sofosbuvir), the hepatitis C drug selling in the United States for $1,000 per pill, for just $10 a pill? Go to Bangladesh or some other country where the drug is about to be produced and sold free of the control of Sovaldi's owner, Gilead Sciences.